Trial Profile
A Phase II Study of Pembrolizumab Monotherapy in Third-line Previously Treated Subjects With Advanced/Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus or Advanced/Metastatic Siewert Type I Adenocarcinoma of the Esophagogastric Junction (KEYNOTE -180)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Oct 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms KEYNOTE-180
- Sponsors Merck Sharp & Dohme
- 10 Nov 2021 Status changed from active, no longer recruiting to completed.
- 07 Feb 2020 Planned End Date changed from 17 Sep 2020 to 29 Oct 2021.
- 16 Sep 2019 Planned End Date changed from 17 Sep 2019 to 17 Sep 2020.